Markets:

Overview

News

Currencies

International

Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

4.620 +0.070 (+1.54%)

Streaming Delayed Price Updated: 2:40 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

May 11, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 07, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

March 31, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

March 17, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!

March 09, 2026

Via AB Newswire

AN2 Therapeutics Announces $40 Million Private Placement Financing

March 09, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

March 03, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

February 17, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

January 12, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

November 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

November 10, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

November 06, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

August 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

August 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

July 23, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

June 30, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

May 29, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 13, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

May 01, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

April 30, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

March 25, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

March 03, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

February 24, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate at Upcoming Investor Conferences

February 20, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

January 29, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate at Upcoming Investor Conferences

November 14, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

November 13, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

October 17, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 28, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

August 16, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.